Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Health Insurance Coverage topic
No spam. Unsubscribe anytime.
Senate passes 'Luca's Law' to allow insurers to consider coverage for PANS/PANDAS treatments
Summary
The Senate approved House Bill 4 11 (named on the floor as "Luca's Law") that clarifies permissive insurance coverage for treatment options used with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS/PANS); families affected by the disorder attended and were recognized on the floor.
The Tennessee Senate voted to pass House Bill 4 11, a measure named on the floor as "Luca's Law," which amends insurance-language to permit consideration of coverage for certain PANS/PANDAS treatments, including antibiotics and other interventions that some medical professionals recommend. The vote on third and final consideration was recorded as 33 ayes, no nays.
Sponsor Senator Watson introduced the bill and the amendment naming the act for a constituent family. Two families attended the floor session and were identified by the sponsor: Christy and Luca Giacco, and Lauren Wilson and her daughter Hannah. Watson described PANDAS/PANS as conditions that can "have a devastating effect on a patient" and their families, and said the bill makes coverage permissive and adds medical-necessity language so that coverage "may consider treatment recommendations by medical professionals."
The adopted language does not mandate coverage; it changes statutory wording to make certain treatments eligible for consideration by insurers when deemed medically necessary. The sponsor said the bill reframed coverage requirements from mandatory to permissive and added medical-necessity criteria and an expectation that recommended treatments be considered.
Supporters said the change improves access for children whose symptoms can onset rapidly and severely at young ages and that it acknowledges medical opinion variability in treating a rare disorder. The bill passed following floor discussion and a recorded vote. The measure now moves toward enactment and any implementing guidance by insurers and regulators will affect actual coverage decisions.
